Open AccessSilencing of lncRNA PART1 inhibits proliferation, invasion and migration of breast cancer cells and promotes the efficacy of cisplatin in breast cancer cells
Author(s) -
Li Zhang,
Jie Zhang,
Chuandou Ni
Publication year - 2020
Publication title -
general physiology and biophysics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.376
H-Index - 39
eISSN - 1338-4325
pISSN - 0231-5882
DOI - 10.4149/gpb_2020008
Subject(s) - gene silencing , cisplatin , cancer research , breast cancer , cell growth , apoptosis , flow cytometry , cell migration , transfection , cancer cell , cancer , cell , gentamicin protection assay , western blot , biology , chemistry , cell culture , microbiology and biotechnology , metastasis , chemotherapy , gene , biochemistry , genetics
LncRNAs have proved to be related to the progression of multiple cancers. The present study aimed to investigate the effect of PART1 on the proliferation, invasion and migration of breast cancer cells and the efficacy of cisplatin in these cells. The expression of lncRNA PART1 in tissues and cells were detected by RT-qPCR analysis which was also used to verify the transfection effects. The cell proliferation, invasion and migration of breast cancer cells were respectively analyzed by CCK-8 assay, transwell assay and wound healing assay. The cell apoptosis was determined by flow cytometry analysis. The detection of CDK2, cyclinE1, P21, MMP3, MMP10, MMP13, Bcl2, Bax, cleaved caspase-3, caspase-3, MDP1, MRP1, GST-π and ABCB1 expression was performed by Western blot analysis. The results revealed that PART1 was increased in breast cancer tissues and cells, silencing of PART1 significantly inhibited cell proliferation, invasion and migration by regulating the expression of relative proteins. In addition, silencing of PART1 obviously improved the sensitivity of breast cancer cells to cisplatin, promoted cell apoptosis, and decreased the expression of breast cancer resistance proteins. In conclusion, silencing of PART1 inhibited proliferation, invasion and migration of breast cancer cells and promoted the efficacy of cisplatin in these cells. Therefore, PART1 may be considered as a novel therapeutic target in breast cancer.